BRIEF-Vanda Pharmaceuticals Provides Update On Vqw-765 Clinical Development Program

2

Oct 14 (Reuters) – Vanda Pharmaceuticals Inc: * VANDA PHARMACEUTICALS PROVIDES UPDATE ON VQW-765 CLINICAL DEVELOPMENT PROGRAM * VANDA PHARMACEUTICALS – PHASE III STUDY OF VQW-765 DID NOT MEET PRIMARY

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)